EIT Pharma: Interview With CEO Leen Kawas About Advancing Therapies For Hepatitis D And Viral Diseases
By Amit Chowdhry ● Oct 6, 2026
EIT Pharma is a biotechnology company focused on advancing therapies for infectious diseases with significant unmet medical needs. The company is developing a portfolio of programs to address serious infectious diseases through rigorous science, disciplined execution, and a patient-centered approach that translates scientific innovation into meaningful real-world impact. Its lead program is Jitixib, or lonafarnib, an investigational oral therapeutic candidate in late-stage development for chronic hepatitis D, and the company is also advancing peginterferon lambda for severe acute viral respiratory infections. Pulse 2.0 interviewed EIT Pharma CEO Leen Kawas to learn more about the company’s strategy, its clinical programs, and its approach to building a biotechnology company around therapies with substantial existing scientific and clinical evidence.